Purpose: Although associated with an overall favorable survival rate, the heterogeneity of
non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and …

Aim This narrative review aims to describe established and emerging urinary biomarkers in
the diagnosis and surveillance of non-muscle invasive bladder cancer. It provides a …

Bladder cancer is one of the most financially burdensome cancers globally, from its
diagnostic to its terminal stages. The impact it imposes on patients and the medical …

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic
diagnosis and urine biomarkers (FISH, Imm Page 1 Health Technology Assessment 2010; Vol …

Due to the lack of disease-specific symptoms, diagnosis and follow-up of bladder cancer has
remained a challenge to the urologic community. Cystoscopy, commonly accepted as a gold …

Abstract Context Bacillus Calmette-Guérin (BCG) is currently the most effective intravesical
therapy for nonmuscle invasive bladder cancer, reducing not only recurrence rates but also …

Objectives With the advent of novel genomic and transcriptomic technologies, new urinary
biomarkers have been identified and tested for bladder cancer (BCa) surveillance. To …

BACKGROUND Urine cytology has been used for screening of bladder cancer but has been
limited by its low sensitivity. UroVysion is a multiprobe fluorescence in situ hybridization …

Urine cytology is the most widely used noninvasive test to detect urothelial tumors. However,
it is limited by its low sensitivity. On the other hand, cystoscopy is the gold standard …

Background A fast, noninvasive test with high sensitivity (SN) and a negative predictive
value (NPV), which is able to detect recurrences in bladder cancer (BC) patients, is needed …